FDA Approves Vivus’ Obesity Drug, Recommends Against Use In High-Risk Heart Patients

A Risk Evaluation and Mitigation Strategy for Qsymia includes prescriber education about the risk of birth defects and limits dispensing to specially certified pharmacies